1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Mochida Pharmaceutical Co., Ltd.

Mochida Pharmaceutical Co., Ltd.

17.80
EUR
+0.20
(+1.14%)
Nov 09Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
2,320.63
2,181.85
2,323.46
2,451.72
5,376.97
2,767.1
2,602.61
2,665.99
2,891.69
2,778.75
2,869.1
2,966.28
3,299.04
- -
Basic EPS, GAAP
244.33
188.63
205.22
214.72
454.49
212.86
117.55
222.27
277.39
178.92
126.8
160.36
222.93
- -
Free Cash Flow per Basic Share
248.06
79.81
337.01
112.75
110.21
282.56
188.9
184.04
114.51
138.07
-272.62
202.93
-283.36
- -
Dividend per Share
69.06
83.99
71.16
68.65
172.37
88.95
85.34
80.32
90.42
90.74
80.51
79.97
79.97
- -
Book Value per Share
2,332.52
2,484.14
2,642.22
2,817.27
3,014.43
3,189.12
3,113.56
3,317.82
3,424.09
3,470.1
3,609.58
3,686.64
3,958.4
- -
Tangible Book Value per Share
2,322.76
2,471.32
2,630.19
2,806.94
3,005.24
3,179.63
3,096.17
3,300.94
3,405.11
3,448.28
3,589.24
3,660.68
3,926.78
- -
Basic Weighted Avg Shares
40
40
40
40
20
40
39
39
38
37
36
35
35
35
Sales/Revenue/Turnover
93,953
87,261
92,274
97,353
106,749
109,652
101,801
102,995
110,179
103,261
102,885
105,159
116,951
- -
Operating Margin (%)
17.67
13.4
13.17
11.68
10.92
9.66
8.65
11.65
13.06
8.24
5.64
7.73
8.68
- -
Depreciation Expense
2,741
3,006
2,764
2,734
2,618
2,917
2,731
2,742
2,689
2,672
2,808
2,940
2,979
- -
Net Income, GAAP
9,892
7,544
8,150
8,526
9,023
8,435
4,598
8,587
10,569
6,649
4,547
5,685
7,903
- -
Effective Tax Rate (%)
37.41
32.29
32.62
26.39
25.52
27.55
26.7
27.83
27.56
26.48
26.19
29.4
29.25
- -
Profit Margin (%)
10.53
8.65
8.83
8.76
8.45
7.69
4.52
8.34
9.59
6.44
4.42
5.41
6.76
- -
Working Capital
64,801
69,461
76,248
81,747
83,577
86,890
88,332
90,083
91,592
90,121
90,589
94,767
91,287
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
10,000
- -
Total Equity
93,688
98,670
104,928
111,868
119,685
125,109
120,663
126,973
128,643
126,773
127,965
130,693
140,324
- -
Return on Invested Capital (%)
10.89
7.98
7.88
7.54
7.4
6.21
5.21
6.91
8.04
4.86
3.35
4.4
5.03
- -
Return on Capital (%)
10.77
7.8
7.98
7.85
7.8
6.89
3.74
6.94
8.27
5.21
3.57
4.4
5.66
- -
Return on Common Equity (%)
10.86
7.84
8.01
7.87
7.79
6.89
3.74
6.94
8.27
5.21
3.57
4.4
5.83
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
10,000
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
- -
- -
- -

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
123,375
119,021
- -
Cash, Cash Equivalents & STI
52,717
31,057
- -
Accounts Receivable, Net
32,901
36,478
- -
Inventories
33,815
36,121
- -
Total Current Liabilities
26,096
27,734
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.01%
2.06%
7.37%
Free Cash Flow
-46.85%
-144.96%
-239.63%
Net Income, GAAP
6.36%
3.68%
39.01%
Sales/Revenue/Turnover
2.56%
2.75%
11.21%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
105,159
2026
- -
- -
- -
- -
116,951
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
160.36
2026
- -
- -
- -
- -
222.93
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
79.97
2026
- -
- -
- -
- -
79.97
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Naoyuki Mochida
Full Time Employees
1,479
Sector
Health technology
Industry
Pharmaceuticals: major
Address
7, Yotsuya 1-chome Tokyo TY Japan 160-8515
IPO Date
May 13, 1963
Website
mochida.co.jp
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Mochida Pharmaceutical Co., Ltd. (4534.T) engages in the research, development, manufacturing, marketing, import and export of pharmaceuticals primarily targeting cardiovascular diseases, obstetrics and gynecology, dermatology, psychiatry, gastroenterology, emergency medicine and other therapeutic areas; key products include LIALDA Tablets for ulcerative colitis, Epadel for hyperlipidemia, TREPROST Inhalation Solution for pulmonary arterial hypertension, QUVIVIQ for insomnia, GOOFICE for chronic constipation, MOVICOL for chronic constipation, Dinagest for dysmenorrhea and endometriosis, biosimilars such as etanercept, adalimumab and teriparatide, and healthcare products like cosmetics and medical equipment. The company operates nationwide in Japan through its head office and branches in Tokyo, branch offices across major cities including Sapporo, Sendai, Nagoya, Osaka, Hiroshima and Fukuoka, manufacturing sites in Gotemba and Fujieda, and distribution centers in Saitama and Osaka, with international expansion into markets such as Vietnam, South Korea, China and the United States. Founded in 1913 and headquartered at 7 Yotsuya 1-chome, Shinjuku-ku, Tokyo, Japan, Mochida maintains a consolidated workforce of 1,508 employees and focuses on innovative research under its corporate creed of "Foresighted, Innovative Research." Recent developments include the September 2025 subscription to a third-party allotment and acquisition of a 20% stake in And Pharma Co., Ltd. for ¥16.2 billion alongside ITOCHU Corporation, making it an equity-method affiliate to leverage R&D and supply chain capabilities; the August 2025 national health insurance drug price listing and launch of LIALDA Tablets 600mg with pediatric indications following partial change approval in June 2025; approval of Epadel in Vietnam in June 2025 and sales partnership in South Korea in December 2024; distribution rights agreement for TYVASO DPI in Japan in October 2024; manufacturing and marketing approval for QUVIVIQ in September 2024; additional indication approval for TREPROST in September 2024; U.S. 510(k) clearance for nerve regeneration material ReFeel in July 2024; and application for tocilizumab biosimilar approval in Japan in March 2025.